Change of Registered Office Address and Principal Place of Business Update on Effective Date

13 November 2026

Further to its announcement on 2 November 2026, Epiminder Limited (ASX:EPI) (**Epiminder** or the **Company**) advises that the effective date of the change of the Company's registered office and principal place of business will be 1 April 2027. From that date, the registered office and principal place of business will be located at:

Suite 1904, Level 19, 7 Spencer Street
Melbourne VIC 3000

From 1 April 2027, the registered office will be open from 9am to 5pm on business days.

ENDS

This announcement has been approved by the Company Secretary.

Investor & Media Enquiries

Gabriella Hold
The Capital Network
P: +61 2 7257 7338
E: gaby@thecapitalnetwork.com.au

Julia Maguire
The Capital Network
P: +61 2 7257 7338
E: julia@thecapitalnetwork.com.au

About Epiminder

Founded in 2017 by Professor Mark Cook together with the Bionics Institute, St Vincent's Hospital, the University of Melbourne and Cochlear Limited, Epiminder is a medical device and information solutions company focused on developing diagnostic and treatment tools for epilepsy and other seizure disorders where continuous monitoring is required. Epiminder is headquartered in Melbourne, Australia and has offices in the United States.

About Minder®

Minder® is a minimally invasive implantable continuous EEG Monitoring (iCEM®) device that provides clinicians and patients with long-term, objective data on brain electrical activity. The system continuously records bilateral subscalp EEG and transmits data via an external wearable and smartphone application to a secure cloud platform. Patients wear the device during their normal daily activities, enabling real-world monitoring over months or years.

The Minder® System was authorised by the FDA via the de novo pathway and is being used in DETECT as a marketed device in a post-market study. The UMPIRE first-in-human multicentre trial, published in Epilepsia (2025), demonstrated Minder's safety and high-quality signal acquisition across extended monitoring periods.